Skip to main content

Table 1 Solicited adverse events post-vaccination (day 0–7) in the Phase 1 US study

From: Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP142) administered intramuscularly with adjuvant system AS01

 

10 μg MSP142/AS01 (N = 6*)

50 μg MSP142/AS01 (N = 20*)

G1

G2

G3

G1

G2

G3

Pain

 Immunization 1

3

2

0

10

6

2

 Immunization 2

1

2

1

7

9

1

 Immunization 3

3

1

0

10

2

3

Redness

 Immunization 1

1

0

1

3

1

4

 Immunization 2

1

0

1

1

2

4

 Immunization 3

2

0

1

3

2

3

Swelling

 Immunization 1

0

1

1

0

2

8

 Immunization 2

0

1

2

3

2

6

 Immunization 3

1

0

3

1

3

10

Fever

 Immunization 1

2

0

0

1

1

1

 Immunization 2

1

2

0

4

4

2

 Immunization 3

2

0

0

3

5

0

Fatigue

 Immunization 1

1

0

0

6

4

1

 Immunization 2

1

1

1

5

7

2

 Immunization 3

1

2

0

7

3

3

Nausea

 Immunization 1

0

0

0

1

0

0

 Immunization 2

1

1

0

1

1

0

 Immunization 3

0

0

0

0

1

1

Headache

 Immunization 1

2

1

0

3

3

1

 Immunization 2

3

0

0

3

6

2

 Immunization 3

1

2

0

2

6

2

Malaise

 Immunization 1

1

0

0

4

1

2

 Immunization 2

0

1

2

3

6

4

 Immunization 3

0

2

0

4

5

3

Myalgia

 Immunization 1

0

0

0

1

2

1

 Immunization 2

2

0

0

4

5

2

 Immunization 3

0

2

0

6

2

3

Joint Pain

 Immunization 1

0

0

0

2

2

0

 Immunization 2

0

1

0

3

2

2

 Immunization 3

0

2

0

4

4

1

Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us